TCGA-D8-A141-01A-11R-A115-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.630
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- INTERFERON_GAMMA_RESPONSE+0.540
- INFLAMMATORY_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.490
- IL6_JAK_STAT3_SIGNALING+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- ANGIOGENESIS+0.420
- HEDGEHOG_SIGNALING+0.410
- COMPLEMENT+0.400
Top 10 suppressed
- E2F_TARGETS-0.570
- OXIDATIVE_PHOSPHORYLATION-0.530
- G2M_CHECKPOINT-0.490
- MYC_TARGETS_V1-0.430
- DNA_REPAIR-0.420
- MYC_TARGETS_V2-0.310
- ADIPOGENESIS-0.270
- MTORC1_SIGNALING-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- CHOLESTEROL_HOMEOSTASIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.945 |
| 2 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.943 |
| 3 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.933 |
| 4 | C3N-02923 | — | cohortMD2 | 0.929 |
| 5 | SRR12202441 | — | — | 0.928 |
| 6 | TCGA-BH-A6R9-01A-21R-A32P-07 | — | A | 0.927 |
| 7 | SRR8613803 | — | D | 0.925 |
| 8 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.924 |
| 9 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.923 |
| 10 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.630 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |